Benefits of Early Health Detection

Imagine catching a #heart or #kidney disease before you feel a single symptom... all with a blink at a retinal camera? That’s exactly what Mediwhale, a South Korean health tech startup, is making possible. Their AI-powered tool, Reti-CVD, uses deep learning to analyze retinal images and predict risks for cardiovascular, kidney, and even eye diseases... no blood tests or CT scans required. Why the #Retina? The retina is a window to your vascular and nervous system. By analyzing blood vessels in the eye, Mediwhale’s AI can spot early warning signs of “silent killers” like heart and kidney disease, which often don’t show symptoms until it’s too late. For patients with chronic conditions like diabetes or obesity, this kind of early detection is a game-changer. How It Works: 1. A quick, non-invasive retina photo is taken. 2. AI scans for biomarkers like blood pressure, kidney function, and cardiovascular risk. 3. The system flags patients as low, medium, or high risk, helping doctors prioritize care. Real-World Impact: - Already used in hospitals across South Korea, Dubai, Italy, and Malaysia. - Over 7,200 cases in 57 Korean hospitals as of August 2024. - Approved in the EU, UK, Korea, and aiming for US FDA approval in 2025. - Raised $12 million in 2024 to expand globally and enhance its AI. Why It Matters: - Fast, affordable, and radiation-free screening. - Helps doctors make smarter, quicker decisions, potentially preventing irreversible harm. - Patients take their health more seriously when they see their risks visualized. The Human Touch: Mediwhale’s founder, Kevin Choi lost much of his vision to glaucoma before he knew he was at risk. His mission is to help others catch disease early, when it’s still treatable. What’s Next? With FDA approval on the horizon and plans to expand into chronic kidney disease prediction, the company is setting a new standard for early, AI-powered preventive care. Would you be willing to give this a wink?

Imagine finding out you have cancer more than three years before any symptoms appear. Thanks to researchers at Johns Hopkins, that idea is no longer just wishful thinking. They’ve developed a cutting-edge blood test that can detect tiny traces of cancer DNA long before today’s standard screenings would ever pick it up. In their study, they ran this multicancer early detection (MCED) test on blood samples from people enrolled in a heart health study. Half of these folks later developed cancer within six months. Remarkably, the test found cancer signals in eight of these future patients—months before their diagnoses. But here’s where it gets even more incredible: for six of these patients, older blood samples were still on file. When researchers checked, four of them already had detectable cancer DNA in their blood more than three years before they ever knew they were sick. Catching cancer that early could be a total game-changer, letting doctors treat it while tumors are still small and more easily curable. As one researcher put it, finding cancer three years sooner could mean it’s “much less advanced and more likely to be curable.” The technology still needs more work before it’s widely available, and there are questions about what to do after a positive test. But experts say tests like this could one day work alongside mammograms or colonoscopies, giving people a much better shot at survival. Research Paper 📄 Detection of cancers three years prior to diagnosis using plasma cell-free DNA. Cancer Discov 2025; DOI: 10.1158/2159-8290.CD-25-0375

Emerging research indicates that what looks like “just getting older” cognitive decline may actually be linked to treatable health issues. Conditions such as high blood pressure, diabetes, poor vision or hearing, persistent inflammation and even chronic infection are increasingly recognised as triggers that damage the brain over time. By harming blood vessels, disrupting metabolism or reducing brain stimulation, these issues can set the stage for dementia long before memory problems are obvious. For example, untreated high blood pressure and diabetes can reduce blood flow or cause vessel damage in the brain, while vision or hearing loss may lead to social isolation and less mental input—both pathways to cognitive decline. Detecting and managing these health conditions early gives a real chance to slow down or delay the onset of dementia. In other words, maintaining overall health is more than just feeling better now—it may protect your brain decades later. The key takeaway is that brain health isn’t only about genetics or age. It’s also about how we look after the rest of our body: the heart, blood vessels, senses, immune system and metabolism. Addressing common conditions proactively isn’t just about avoiding disease—it’s an essential part of keeping our minds sharp as we age.

Swedish scientists at the Karolinska Institute have unveiled a groundbreaking microchip implant that can detect cancer up to four years before any symptoms appear. This tiny device — smaller than a grain of rice — constantly scans the bloodstream for circulating tumor DNA and early cancer-linked proteins. Powered by advanced nanotech sensors and AI analysis, the chip sends instant alerts to a smartphone app the moment it detects unusual biomarker activity. In trials with 300 participants, it identified pancreatic, ovarian, lung, and colon cancers 3–4 years earlier than today’s imaging tools. The implant lasts a decade, costs about $500, and can also track inflammation and cardiac markers, helping predict heart disease and autoimmune disorders. Sweden aims to offer it to citizens over 40 by 2027 — a move that could redefine preventive healthcare. Experts say this innovation could boost survival rates, lower medical costs, and reduce the need for invasive biopsies, making ultra-early detection one of humanity’s strongest weapons against cancer.

Researchers at Johns Hopkins University have made a potentially game-changing discovery in cancer diagnostics. They found that fragments of tumor DNA, known as circulating tumor DNA (ctDNA), can be detected in the bloodstream as early as three years before a clinical cancer diagnosis. This breakthrough opens up an extended window of opportunity for early cancer detection, which is critical for improving survival rates and enabling less invasive treatment options. The discovery was part of ongoing research into liquid biopsy techniques, which aim to identify cancer through simple blood tests instead of traditional imaging or tissue biopsies. These ctDNA fragments are shed by tumors into the bloodstream and can carry mutations specific to different types of cancers. Detecting them early may lead to personalized screening strategies, especially for individuals at higher risk. A study published in Nature Communications (2020) supports this claim. It discussed how early traces of cancer-related genetic alterations can be detected years before conventional methods would identify the disease. Such research is the backbone of companies like GRAIL, which are developing multi-cancer early detection tests based on similar principles. While the detection of tumor DNA years in advance is promising, it's important to note that: Not all cancers shed enough ctDNA to be detected early. Further validation across larger and more diverse populations is needed. There's a risk of false positives or overdiagnosis that must be managed. Nevertheless, this innovation represents a revolutionary leap forward in the field of oncology, offering hope for earlier intervention and better patient outcomes.

A simple blood test may soon reveal cancer years before *any* symptoms appear. The number of lives saved would be simply enormous. Scientists at Johns Hopkins have made a significant breakthrough in early cancer detection, revealing that tumor-derived genetic mutations can be identified in blood samples up to three years before clinical diagnosis. Published in Cancer Discovery, the study utilized highly sensitive sequencing techniques to analyze archived plasma from the NIH-funded Atherosclerosis Risk in Communities study. In several cases, cancer signals were found in blood collected more than three years before any symptoms appeared—offering a potential window for earlier, life-saving intervention. The research strengthens the promise of multicancer early detection (MCED) tests, which aim to identify cancer signals in the bloodstream. According to the study, participants with positive MCED results were typically diagnosed within four months, but evidence from earlier samples shows that cancerous mutations were detectable far in advance. This could mark a paradigm shift in cancer screening, giving clinicians crucial lead time and improving odds for successful treatment. Still, scientists stress the importance of determining the best clinical path forward after a positive early test. learn more https://lnkd.in/dA6r72qH

Most adults think they’ll ‘feel it’ if something is wrong with their heart. They won’t. That’s exactly why so many never make it to prevention. Most heart problems don’t start with chest pain, they start quietly. And often, by the time symptoms appear, prevention is no longer an option… it’s damage control. As a cardiologist, I see it every week: people who felt perfectly fine until something suddenly wasn’t. The truth? Heart disease is often silent, but today, we have tools that can detect those risks long before trouble begins. Here’s what I wish more adults knew 👇 🔬 Your genes can whisper warnings. Genetic testing can identify inherited risks decades before symptoms. It’s one of the most powerful ways to personalise prevention. Cardiac CT calcium scoring: A quick, non-invasive scan that measures tiny calcium deposits in your arteries, often years before blood tests show a problem. 🏃♂️ Stress testing isn’t just for athletes. For those who can’t do treadmill tests, pharmacological stress tests safely mimic exercise and uncover hidden coronary disease. 📆 When to start → In your 20s–30s: get your baseline, blood pressure, cholesterol, ECG. → In your 40s: if you have risk factors or a family history, add imaging or stress testing. → After 50: make heart checks a yearly habit. 🧬 Go beyond “good and bad cholesterol” Tests like lipoprotein(a), ApoB, and inflammatory markers can reveal risks that traditional panels miss. Early detection changes everything Most heart attacks don’t come out of nowhere, they come from risks that were never measured. When we catch them early, we can act early. And that saves lives.

The future is here: a simple blood test can 𝐝𝐞𝐭𝐞𝐜𝐭 𝐜𝐚𝐧𝐜𝐞𝐫 𝐭𝐡𝐫𝐞𝐞 𝐲𝐞𝐚𝐫𝐬 𝐛𝐞𝐟𝐨𝐫𝐞 𝐬𝐲𝐦𝐩𝐭𝐨𝐦𝐬 𝐚𝐩𝐩𝐞𝐚𝐫, but most aren’t aware of its existence 🩸 For decades, cancer detection has been a game of waiting - waiting for symptoms, waiting for lumps, waiting for pain. But something revolutionary is happening now at The Johns Hopkins University. ✨ 📌 Their multicancer early detection (MCED) blood test identifies tumor DNA fragments circulating in your bloodstream years before any clinical signs appear. 📌 The technology works by detecting circulating tumor DNA (ctDNA) - tiny genetic fragments that cancers shed into the bloodstream long before traditional screening methods could catch them. These breakthrough capabilities exist because 𝐜𝐚𝐧𝐜𝐞𝐫 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐡𝐚𝐬 𝐫𝐞𝐚𝐜𝐡𝐞𝐝 𝐚 𝐭𝐢𝐩𝐩𝐢𝐧𝐠 𝐩𝐨𝐢𝐧𝐭. 📍 Cancer will affect a staggering 𝟏 𝐢𝐧 𝟐 𝐩𝐞𝐨𝐩𝐥𝐞 in their lifetime.  📍 Early detection can 𝐢𝐧𝐜𝐫𝐞𝐚𝐬𝐞 𝐬𝐮𝐫𝐯𝐢𝐯𝐚𝐥 𝐫𝐚𝐭𝐞𝐬 𝐛𝐲 𝐮𝐩 𝐭𝐨 𝟗𝟎% for many cancers. Medical researchers knew early detection was crucial. But they needed technology sensitive enough to find signals in the noise. Let me explain the breakthrough…⤵️ Researchers analyzed blood samples from 52 people - 26 who developed cancer within six months and 26 who remained cancer-free. Eight participants tested positive for tumor DNA at sampling time. All eight were diagnosed with cancer within four months. The 𝐦𝐨𝐬𝐭 𝐫𝐞𝐦𝐚𝐫𝐤𝐚𝐛𝐥𝐞 finding? When they examined blood samples taken 3.1 to 3.5 years earlier from six participants, four still showed detectable tumor mutations. Dr. Yuxuan Wang led this groundbreaking research. Published in Cancer Discovery in 2024, his team proved that "three years earlier provides time for intervention. The tumors are likely to be much less advanced and more likely to be curable." Meanwhile, Dr. Nickolas Papadopoulos emphasized the clinical implications: detecting cancers years before diagnosis could fundamentally change patient outcomes, though appropriate follow-up protocols still need development. The momentum is building fast: 📌 Multiple MCED tests are advancing through clinical trials  📌 Liquid biopsy market projected to reach $6.8 billion by 2025 But this isn't just about technology. It's about hope. We're no longer waiting for cancer to announce itself. We're catching it before it even knows it's there, turning years of reactive treatment into proactive intervention. What disease will early detection technology revolutionize next? #earlydetection #cancerscreening #liquidbiopsy #healthtech

As an oncologist, I’ve had more conversations than I can count with patients hearing the words “late-stage cancer” for the first time. I’ve sat with them in that moment of shock, walked with them through the fear, the hope and the fight. And there is one truth I’ve learned: when we catch cancer early, we change everything. We save lives. We spare families years of unnecessary heartache. We prevent the crushing financial, physical, and emotional burdens that come when the disease is found too late. That’s why at St. Elizabeth Healthcare we’ve made early detection a cornerstone of our mission. We’ve invested heavily in screening and prevention, particularly in lung cancer, where Kentucky leads the nation in incidence rates. Lung cancer remains the deadliest cancer in the U.S., but when caught early, survival rates soar. In coming years, it is likely that more sensitive blood-based cancer multicancer early detection screening tests will replace screening scans—and once FDA approved, should be widely available. The promise here is enormous: MCED tests could save countless lives, reduce the need for aggressive and expensive treatments, and give patients hope when it matters most. But science can only save lives if public policy keeps up. The Nancy Gardner Sewell Medicare Multi-Cancer Early Detection (MCED) Screening Coverage Act is designed to do exactly that. It would allow Medicare to cover FDA-approved tests without years of bureaucratic delay—just as it did for other lifesaving cancer screenings. Seniors who face the highest cancer risk deserve that same timely access. Read below for my thoughts on what we can do right here. Lisa A. Lacasse American Cancer Society Association of Cancer Care Centers American Cancer Society Cancer Action Network (ACS CAN) #MCED https://lnkd.in/giSssudD

If we don't act, 1–2 billion people will die from cancer in the next 100 years. Let that sink in. This “thought experiment” reveals the staggering cost of maintaining the status quo. Today: ~10 million people die globally from cancer every year. By 2050: That number is projected to rise to 18–19 million annually due to population growth and aging. The 100-Year Toll (No Change): 1 to 2 BILLION lives. But this future is NOT fixed. Cancer has an Achilles’ heel: early detection. When found early, outcomes change dramatically. For example, breast cancer detected at Stage 1 has ~99% 5-year survival — but detected at Stage 4, survival drops to ~30%. This pattern holds across nearly every major cancer type. Early detection isn’t just beneficial — it is the single most powerful lever we have to reduce mortality at scale. And the next decade offers unprecedented potential to bend the cancer curve. Advances in AI-driven screening, multi-omics, and precision risk assessment are accelerating faster than medicine can adopt them. Even a 20–30% global reduction in cancer deaths would save hundreds of millions of lives this century. This is exactly why at Human Longevity, we launched the $1 Million Cancer Pledge. We provide advanced early-detection screening for multiple top cancers for those who need it most. Our mission is simple: 👉 Find cancers earlier. Save more lives. Build a global model for proactive longevity. Our focus on early detection, precision screening, and preventive health is not optional — it is essential. The next decade will matter more than the next century. Cancer is not inevitable. Our inaction is.